9 Meters Biopharma (NMTR) Stock Price, News & Analysis

Company Overview

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel biologic therapies for gastrointestinal, liver and immune-mediated diseases. The company’s lead candidate, GMCT02, is being evaluated in a Phase 2 clinical trial for ulcerative colitis. Beyond GMCT02, 9 Meters Biopharma’s pipeline includes additional antibody-based and immunomodulatory programs targeting inflammatory bowel disease, cholestatic liver disease and other conditions with high unmet medical need.

9 Meters Biopharma employs a lean development model, in-licensing product candidates from academic and philanthropic partners and advancing them through clinical development. Its research strategy emphasizes targeted immune regulation and tissue-specific delivery to address the underlying pathophysiology of chronic gastrointestinal disorders. The company collaborates with leading clinical investigators and academic centers to conduct its trials across North America.

Headquartered in Vancouver, British Columbia, with additional offices in Boston, Massachusetts, 9 Meters Biopharma was formed in 2021 following a strategic merger and subsequent public listing on NASDAQ. The company is led by Chief Executive Officer Gregory M. Postel, who has over two decades of experience in biotechnology leadership and corporate development. 9 Meters Biopharma continues to expand its footprint through both internal discovery efforts and external licensing partnerships aimed at bringing new therapies to patients worldwide.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 315,915 shs
• Market Capitalization: $1.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NMTR Stock Analysis - Frequently Asked Questions

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

9 Meters Biopharma shares reverse split before market open on Tuesday, October 18th 2022.The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 9 Meters Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), SNDL (SNDL), NIO (NIO), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NMTR
• CIK: 1551986
• Web: www.9meters.com
• Phone: (919) 275-1933
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -584.97%
• Return on Assets: -159.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.59
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,336,000
• Free Float: 13,992,000
• Market Cap: $1.04 million
• Optionable: No Data
• Beta: 1.36